---
created: 2025-04-13
updated: 2025-04-13T10:52
id: PRi,{`#`th
specialty: endo
specialty_id: 60
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/amboss::endocrinology
  - "source/ak-step1-v11:": 
  - theme/b&b::08-endocrinology::03-pancreas::04-treatment-of-diabetes
  - "source/ak-step1-v11:": 
  - theme/firstaid::08-endocrine::05-pharm::01-diabetes-mellitus-therapy
  - "source/ak-step1-v11:": 
  - theme/firstaid::08-endocrine::05-pharm::01-diabetes-mellitus-therapy::meglitinides
  - "source/ak-step1-v11:": 
  - theme/firstaid::08-endocrine::05-pharm::01-diabetes-mellitus-therapy::sulfonylureas
  - "source/ak-step1-v11:": 
  - theme/ome::14-endocrine::05-pancreas::03-diabetes-pharm
  - "source/ak-step1-v11:": 
  - source/ome-banner::clinical::07-endocrinology::06-outpatient-diabetes
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::07-endocrine::04-sulfonylureas-and-meglitinides
  - "source/ak-step1-v11:": 
  - theme/pixorize::02-biochem::23-diabetes-drugs::04-meglitinides
  - "source/ak-step1-v11:": 
  - theme/pixorize::02-biochem::23-diabetes-drugs::05-first-gen-sylfonylureas
  - "source/ak-step1-v11:": 
  - theme/pixorize::02-biochem::23-diabetes-drugs::06-second-gen-sylfonylureas
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::07-diabetes::first-gen-sulfonylureas
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::07-diabetes::meglitinides
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::07-diabetes::second-gen-sulfonylureas
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::05-gi-&-endocrine::02-diabetes::01-insulin,-sulfonylureas,-meglitinides,-glp-1-agonists,-dpp-4-inhibitors
  - "source/ak-step1-v11:": 
  - theme/uworld::100-999::600-699::606
  - "source/ak-step1-v11:": 
  - theme/uworld::1000-9999::8000-8999::8531
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::11000-11999::11565
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::15000-15999::15881
  - source/ak-step1-v11::^other::^highyield::3-highyield-temporary
  - source/ak-step1-v11::^systems::endocrine::pharmacology
  - source/ak-step2-v11::!shelf::fm::no-dupes
  - source/ak-step2-v11::!shelf::im::no-dupes
  - "source/ak-step2-v11:": 
  - theme/ome::07-endocrinology::05-outpatient-diabetes
  - "source/ak-step2-v11:": 
  - theme/resources-by-rotation::fm::ome::endo::outpatient-dm
  - "source/ak-step2-v11:": 
  - theme/resources-by-rotation::im::ome::endo::outpatient-dm
  - source/ak-step2-v11::original-decks::dorian::fam::ome::endo::outpatient-dm
  - source/ak-step2-v11::original-decks::dorian::im::ome::endo::outpatient-dm"
type: flashcard
---

# Question
Sulfonylureas (eg, glipizide, glyburide, glimepiride, gl- prefix) and meglitinides have significant risk of causing **hypoglycemia** as a possible side effect; They inhibit the ATP-sensitive K+ channel on the pancreatic beta cell membrane

---

# Answer
glucose-INDEPENDENT insulin secretion == high risk of hypoglicemia These drugs bypass regulation of insulin release; gl- prefix